Zelenectide pevedotin is under clinical development by Bicycle Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zelenectide pevedotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zelenectide pevedotin overview
BT-8009 is under development for the treatment of solid tumors like metastatic urothelial (transitional cell) carcinoma, renal cancer, ureter cancer, urethral cancer, non-small cell lung cancer, esophageal cancer, bladder cancer, urothelial carcinoma, pancreatic cancer, gastric cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, urothelial (transitional cell) carcinoma cancer, pancreatic cancer, breast cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or ovarian cancer tumors, head and neck cancer and triple negative breast cancer. The drug candidate is a bicyclic peptide conjugate being developed based on bicyclic peptide technology. It acts by targeting nectin-4 linked to the cytotoxin monomethyl auristatin E (MMAE) by a molecular spacer and cleavable linker. It is administered through intravenous route.
Bicycle Therapeutics overview
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of molecules for treating cancers and other debilitating diseases. The company’s Bicycle Toxin Conjugates (BTC) pipeline includes zelenectide pevedotin, BT1718 and BT5528 to indicate metastatic urothelial cancer, epha2 (ephrin type-a receptor 2), MT1-MMP (membrane type 1-matrix metalloproteinase) and solid tumor. Its Immuno-oncology pipeline products include BT7480, BT7401 and BT7455. Bicycle Therapeutics collaborates with other biotechnology companies to develop bicyclic peptide inhibitors. The company operates in the UK and the US. Bicycle Therapeutics is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Zelenectide pevedotin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
